{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:31:06Z","timestamp":1774625466025,"version":"3.50.1"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Aripiprazole is a second-generation antipsychotic, efficacious in patients with schizophrenia during acute episodes. Due to its pharmacological profile, aripiprazole may be of interest in patients with specific clinical profiles who have not been studied extensively in randomised clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To capture experience with aripiprazole in everyday psychiatric practice using the Delphi method in order to inform decision-making on the use of aripiprazole for the treatment of patients with schizophrenia in clinical situations where robust evidence from clinical trials is lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The scope of the survey was defined as the management of schizophrenia in adults. A systematic literature review was performed to identify the different clinical situations in which aripiprazole has been studied, and to describe the level of clinical evidence. Clinical profiles to include in the Delphi survey were selected if there was a clear interest in terms of medical need but uncertainty over the efficacy of aripiprazole. For each clinical profile retained, five to seven specific statements were generated and included in a questionnaire. The final 41-item questionnaire was proposed to a panel of 406 French psychiatrists with experience in the treatment of schizophrenia. Panellists rated their level of agreement using a Likert scale. A second round of voting on eleven items was organised to clarify points for which a consensus was not obtained in the first round.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five clinical profiles were identified in the literature review (persistent negative symptoms, pregnancy, cognitive dysfunction, addictive comorbidity and clozapine resistance). Sixty-two psychiatrists participated in the first round of the Delphi survey and 33 in the second round. A consensus was obtained for 11 out of 41 items in the first round and for 9\/11 items in the second round. According to the panellists\u2019 clinical experience, aripiprazole can be used as maintenance treatment for pregnant women, is relevant to preserve cognitive function and can be considered an option in patients with a comorbid addictive disorder or with persistent negative symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings may help physicians in choosing relevant ways to use aripiprazole and highlight areas where more research is needed to widen the evidence base.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12888-022-04008-9","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T06:02:43Z","timestamp":1653717763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study"],"prefix":"10.1186","volume":"22","author":[{"given":"Pierre-Michel","family":"Llorca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Nuss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9ric","family":"Fakra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Alamome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Drapier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wissam","family":"El Hage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Jardri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Mouchabac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-No\u00eblle","family":"Vacheron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Azorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"issue":"5","key":"4008_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/15622975.2012.696143","volume":"13","author":"A Hasan","year":"2012","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318\u201378.","journal-title":"World J Biol Psychiatry"},{"issue":"4","key":"4008_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1517\/eoid.12.4.655.23750","volume":"12","author":"PE Keck Jr","year":"2003","unstructured":"Keck PE Jr, Mcelroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs. 2003;12(4):655\u201362.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"4008_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.encep.2018.10.003","volume":"44","author":"N Simon","year":"2018","unstructured":"Simon N, Azorin JM. Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact. Encephale. 2018;44(6):558\u201364.","journal-title":"Encephale"},{"issue":"6","key":"4008_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1517\/13543784.16.6.771","volume":"16","author":"M Wood","year":"2007","unstructured":"Wood M, Reavill C. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007;16(6):771\u20135.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"4008_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2174\/138161210790361461","volume":"16","author":"RB Mailman","year":"2010","unstructured":"Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16(5):488\u2013501.","journal-title":"Curr Pharm Des"},{"issue":"6","key":"4008_CR6","doi-asserted-by":"publisher","first-page":"e100069","DOI":"10.1371\/journal.pone.0100069","volume":"9","author":"RC Kling","year":"2014","unstructured":"Kling RC, Tschammer N, Lanig H, Clark T, Gmeiner P. Active-state model of a dopamine D2 receptor-Galphai complex stabilized by aripiprazole-type partial agonists. PLoS ONE. 2014;9(6):e100069.","journal-title":"PLoS ONE"},{"issue":"1","key":"4008_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.biopsych.2016.10.011","volume":"81","author":"NM Urs","year":"2017","unstructured":"Urs NM, Peterson SM, Caron MG. New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy. Biol Psychiatry. 2017;81(1):78\u201385.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"4008_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrd3954","volume":"12","author":"T Kenakin","year":"2013","unstructured":"Kenakin T, Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov. 2013;12(3):205\u201316.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"4008_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrd3954-c2","volume":"12","author":"T Kenakin","year":"2013","unstructured":"Kenakin T, Christopoulos A. Measurements of ligand bias and functional affinity. Nat Rev Drug Discov. 2013;12(6):483.","journal-title":"Nat Rev Drug Discov"},{"key":"4008_CR10","first-page":"CD006569","volume":"1","author":"P Khanna","year":"2014","unstructured":"Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014;1:CD006569.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"4008_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41537-021-00158-z","volume":"7","author":"DD Kim","year":"2021","unstructured":"Kim DD, Barr AM, Lian L, Yuen JWY, Fredrikson D, Honer WG, et al. Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis. NPJ Schizophr. 2021;7(1):29.","journal-title":"NPJ Schizophr"},{"issue":"9896","key":"4008_CR12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"4008_CR13","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.clinthera.2010.01.021","volume":"32","author":"E Stip","year":"2010","unstructured":"Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther. 2010;32(Suppl 1):S3-20.","journal-title":"Clin Ther"},{"key":"4008_CR14","first-page":"2635","volume":"11","author":"G Di Sciascio","year":"2015","unstructured":"Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015;11:2635\u201347.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"4008_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1017\/S1092852920001510","volume":"26","author":"D Hernandez-Huerta","year":"2021","unstructured":"Hernandez-Huerta D, Morillo-Gonzalez J. Dopamine D3 partial agonists in the treatment of psychosis and substance use disorder comorbidity: a pharmacological alternative to consider? CNS Spectr. 2021;26(5):444\u20135.","journal-title":"CNS Spectr"},{"key":"4008_CR16","doi-asserted-by":"crossref","unstructured":"Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn\u2019t. BMJ. 1996;312(7023):71\u20132.","DOI":"10.1136\/bmj.312.7023.71"},{"key":"4008_CR17","volume-title":"Metaplan\u00ae Basic Techniques. Moderating group discussions using the Metaplan approach","author":"G Metaplan","year":"2021","unstructured":"Metaplan G. Metaplan\u00ae Basic Techniques. Moderating group discussions using the Metaplan approach. 2021."},{"key":"4008_CR18","volume-title":"The Delphi Method: an experimental study in group opinion","author":"N Dalkey","year":"1969","unstructured":"Dalkey N. The Delphi Method: an experimental study in group opinion. Santa Monica, USA: RAND Corporation; 1969."},{"issue":"2","key":"4008_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0040-1625(70)90161-7","volume":"2","author":"M Turoff","year":"1970","unstructured":"Turoff M. The design of a policy Delphi. Technol Forecasting Soc Change. 1970;2(2):149\u201371.","journal-title":"Technol Forecasting Soc Change"},{"issue":"4","key":"4008_CR20","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","volume":"32","author":"F Hasson","year":"2000","unstructured":"Hasson F, Keeney S, Mckenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32(4):1008\u201315.","journal-title":"J Adv Nurs"},{"key":"4008_CR21","first-page":"598","volume":"22","author":"Iqbal SP-Y, L","year":"2009","unstructured":"Iqbal SP-Y, L. The Delphi method. Psychologist. 2009;22:598\u2013601.","journal-title":"Psychologist"},{"issue":"1","key":"4008_CR22","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1192\/j.eurpsy.2020.115","volume":"64","author":"S Galderisi","year":"2021","unstructured":"Galderisi S, De Hert M, Del Prato S, Fagiolini A, Gorwood P, Leucht S, et al. Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. Eur Psychiatry. 2021;64(1):e7.","journal-title":"Eur Psychiatry"},{"issue":"2","key":"4008_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/15622975.2015.1132007","volume":"17","author":"M Garriga","year":"2016","unstructured":"Garriga M, Pacchiarotti I, Kasper S, Zeller SL, Allen MH, Vazquez G, et al. Assessment and management of agitation in psychiatry: Expert consensus. World J Biol Psychiatry. 2016;17(2):86\u2013128.","journal-title":"World J Biol Psychiatry"},{"issue":"10","key":"4008_CR24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0004867415600891","volume":"49","author":"AF Jorm","year":"2015","unstructured":"Jorm AF. Using the Delphi expert consensus method in mental health research. Aust N Z J Psychiatry. 2015;49(10):887\u201397.","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"4008_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3109\/13651501.2014.1002501","volume":"19","author":"L San","year":"2015","unstructured":"San L, Serrano M, Canas F, Romero SL, Sanchez-Cabezudo A, Villar M. Towards a pragmatic and operational definition of relapse in schizophrenia: A Delphi consensus approach. Int J Psychiatry Clin Pract. 2015;19(2):90\u20138.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"7","key":"4008_CR26","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.","journal-title":"PLoS Med"},{"key":"4008_CR27","first-page":"1","volume-title":"Niveau de preuve et gradation des recommandations de bonne pratique","author":"Haute Autorite De Sant\u00e9","year":"2013","unstructured":"Sant\u00e9 Haute Autorite De. Niveau de preuve et gradation des recommandations de bonne pratique. St Denis: HAS; 2013. p. 1\u201392."},{"issue":"4","key":"4008_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67(4):401\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"4008_CR29","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/schbul\/sbl057","volume":"33","author":"RW Buchanan","year":"2007","unstructured":"Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33(4):1013\u201322.","journal-title":"Schizophr Bull"},{"issue":"Suppl 2","key":"4008_CR30","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1093\/schbul\/sbt158","volume":"40 Suppl","author":"B Kirkpatrick","year":"2014","unstructured":"Kirkpatrick B. Progress in the study of negative symptoms. Schizophrenia bulletin. 2014;40 Suppl(Suppl 2):S101-6.","journal-title":"Schizophrenia bulletin"},{"issue":"2","key":"4008_CR31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/schbul\/sbj053","volume":"32","author":"B Kirkpatrick","year":"2006","unstructured":"Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214\u20139.","journal-title":"Schizophr Bull"},{"key":"4008_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/schbul\/1.11.61","volume":"11","author":"JS Strauss","year":"1974","unstructured":"Strauss JS, Carpenter WT Jr, Bartko JJ. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophrenia bulletin. 1974;11:61\u20139.","journal-title":"Schizophrenia bulletin"},{"key":"4008_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.schres.2016.05.015","volume":"186","author":"A Aleman","year":"2017","unstructured":"Aleman A, Lincoln TM, Bruggeman R, Melle I, Arends J, Arango C, et al. Treatment of negative symptoms: Where do we stand, and where do we go? Schizophr Res. 2017;186:55\u201362.","journal-title":"Schizophr Res"},{"issue":"3","key":"4008_CR34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4088\/JCP.08m04250yel","volume":"71","author":"J Bobes","year":"2010","unstructured":"Bobes J, Arango C, Garcia-Garcia M, Rejas J. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010;71(3):280\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"4008_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/wps.20167","volume":"13","author":"S Galderisi","year":"2014","unstructured":"Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014;13(3):275\u201387.","journal-title":"World Psychiatry"},{"issue":"2","key":"4008_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.wpsyc.2012.05.004","volume":"11","author":"PD Harvey","year":"2012","unstructured":"Harvey PD, Strassnig M. Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. World Psychiatry. 2012;11(2):73\u20139.","journal-title":"World Psychiatry"},{"issue":"3","key":"4008_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0920-9964(00)00146-8","volume":"49","author":"C Tek","year":"2001","unstructured":"Tek C, Kirkpatrick B, Buchanan RW. A five-year followup study of deficit and nondeficit schizophrenia. Schizophr Res. 2001;49(3):253\u201360.","journal-title":"Schizophr Res"},{"issue":"6207","key":"4008_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/bmj.280.6207.66","volume":"280","author":"TJ Crow","year":"1980","unstructured":"Crow TJ. Molecular pathology of schizophrenia: more than one disease process? BMJ. 1980;280(6207):66\u20138.","journal-title":"BMJ"},{"key":"4008_CR39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1192\/bjp.137.4.379","volume":"137","author":"AV Mackay","year":"1980","unstructured":"Mackay AV. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry. 1980;137:379\u201383.","journal-title":"Br J Psychiatry"},{"issue":"2\u20133","key":"4008_CR40","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.schres.2013.07.026","volume":"150","author":"C Arango","year":"2013","unstructured":"Arango C, Garibaldi G, Marder SR. Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res. 2013;150(2\u20133):346\u201352.","journal-title":"Schizophr Res"},{"issue":"4","key":"4008_CR41","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/schbul\/sbu170","volume":"41","author":"P Fusar-Poli","year":"2015","unstructured":"Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, et al. Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull. 2015;41(4):892\u20139.","journal-title":"Schizophr Bull"},{"issue":"9657","key":"4008_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31\u201341.","journal-title":"Lancet"},{"issue":"7","key":"4008_CR43","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00406-015-0596-y","volume":"265","author":"HJ M\u00f6ller","year":"2015","unstructured":"M\u00f6ller HJ, Czobor P. Pharmacological treatment of negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2015;265(7):567\u201378.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"4008_CR44","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.pnpbp.2006.09.015","volume":"31","author":"CI Mitsonis","year":"2007","unstructured":"Mitsonis CI, Dimopoulos NP, Mitropoulos PA, Kararizou EG, Katsa AN, Tsakiris FE, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):373\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"Suppl 1","key":"4008_CR45","first-page":"S245","volume":"27","author":"F Franza","year":"2015","unstructured":"Franza F, Fasano V, De Guglielmo S, Solomita B. Management of primary negative symptoms in schizophrenia: an one-year observational study. Psychiatr Danub. 2015;27(Suppl 1):S245\u20139.","journal-title":"Psychiatr Danub"},{"issue":"1","key":"4008_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/01.jcp.0000196417.44847.0b","volume":"26","author":"ID Glick","year":"2006","unstructured":"Glick ID, Duggal V, Hodulik C. Aripiprazole as a dopamine partial agonist: positive and negative effects. J Clin Psychopharmacol. 2006;26(1):101\u20133.","journal-title":"J Clin Psychopharmacol"},{"issue":"3 Pt 1","key":"4008_CR47","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0013-7006(07)92047-3","volume":"33","author":"D Levoyer","year":"2007","unstructured":"Levoyer D, Drapier D, Fadier-Salic\u00e9 G, Millet B. Clinical impact of aripiprazole in patients suffering from schizophrenia. Encephale. 2007;33(3 Pt 1):332\u20138.","journal-title":"Encephale"},{"issue":"7","key":"4008_CR48","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/pcn.12167","volume":"68","author":"CH Tsai","year":"2014","unstructured":"Tsai CH, Chen TT, Huang WL. Combination of escitalopram and aripiprazole causes significant improvement of negative symptoms of simple schizophrenia. Psychiatry Clin Neurosci. 2014;68(7):582\u20133.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"4008_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.euroneuro.2018.11.1103","volume":"29","author":"M Galbally","year":"2019","unstructured":"Galbally M, Frayne J, Watson SJ, Snellen M. Psychopharmacological prescribing practices in pregnancy for women with severe mental illness: A multicentre study. Eur Neuropsychopharmacol. 2019;29(1):57\u201365.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"4008_CR50","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/2042098614522682","volume":"5","author":"M Galbally","year":"2014","unstructured":"Galbally M, Snellen M, Power J. Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. Therapeutic Adv Drug Safety. 2014;5(2):100\u20139.","journal-title":"Therapeutic Adv Drug Safety"},{"issue":"4","key":"4008_CR51","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3109\/01674829809025699","volume":"19","author":"LJ Miller","year":"1998","unstructured":"Miller LJ, Finnerty M. Family planning knowledge, attitudes and practices in women with schizophrenic spectrum disorders. J Psychosom Obstet Gynaecol. 1998;19(4):210\u20137.","journal-title":"J Psychosom Obstet Gynaecol"},{"issue":"15","key":"4008_CR52","doi-asserted-by":"publisher","first-page":"5594","DOI":"10.3390\/ijerph17155594","volume":"17","author":"A Gonz\u00e1lez-Rodr\u00edguez","year":"2020","unstructured":"Gonz\u00e1lez-Rodr\u00edguez A, Gu\u00e0rdia A, \u00c1lvarezPedrero A, Betriu M, Cobo J, Acebillo S, et al. Women with Schizophrenia over the Life Span: Health Promotion, Treatment and Outcomes. Int J Environ Res Public Health. 2020;17(15):5594.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"4008_CR53","first-page":"15","volume":"49","author":"AM Posada Correa","year":"2020","unstructured":"Posada Correa AM, Andrade Carrillo RA, Suarez Vega DC, G\u00f3mez Cano S, Agudelo Arango LG, Tabares Builes LF, et al. Sexual and Reproductive Health in Patients with Schizophrenia and Bipolar Disorder. Revista Colombiana de psiquiatria (English ed). 2020;49(1):15\u201322.","journal-title":"Revista Colombiana de psiquiatria (English ed)"},{"issue":"4","key":"4008_CR54","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4103\/IJPSYM.IJPSYM_134_19","volume":"41","author":"B Sethuraman","year":"2019","unstructured":"Sethuraman B, Rachana A, Kurian S. Knowledge, Attitude, and Practice Regarding Contraception among Women with Schizophrenia: An Observational Study from South India. Indian J Psychol Med. 2019;41(4):323\u201330.","journal-title":"Indian J Psychol Med"},{"key":"4008_CR55","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2147\/TCRM.S70545","volume":"10","author":"P Ifteni","year":"2014","unstructured":"Ifteni P, Moga MA, Burtea V, Correll CU. Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report. Ther Clin Risk Manag. 2014;10:901\u20134.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"4008_CR56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00404-010-1706-8","volume":"283","author":"NR Matevosyan","year":"2011","unstructured":"Matevosyan NR. Pregnancy and postpartum specifics in women with schizophrenia: a meta-study. Arch Gynecol Obstet. 2011;283(2):141\u20137.","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"4008_CR57","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1046\/j.1440-1614.1999.00641.x","volume":"33","author":"M Snellen","year":"1999","unstructured":"Snellen M, Mack K, Trauer T. Schizophrenia, mental state, and mother-infant interaction: examining the relationship. Aust N Z J Psychiatry. 1999;33(6):902\u201311.","journal-title":"Aust N Z J Psychiatry"},{"issue":"1\u20132","key":"4008_CR58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.psychres.2007.05.012","volume":"159","author":"MW Wan","year":"2008","unstructured":"Wan MW, Penketh V, Salmon MP, Abel KM. Content and style of speech from mothers with schizophrenia towards their infants. Psychiatry Res. 2008;159(1\u20132):109\u201314.","journal-title":"Psychiatry Res"},{"issue":"3","key":"4008_CR59","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.infbeh.2008.04.003","volume":"31","author":"MW Wan","year":"2008","unstructured":"Wan MW, Warren K, Salmon MP, Abel KM. Patterns of maternal responding in postpartum mothers with schizophrenia. Infant Behav Dev. 2008;31(3):532\u20138.","journal-title":"Infant Behav Dev"},{"issue":"7","key":"4008_CR60","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/archgenpsychiatry.2011.1870","volume":"69","author":"R Bod\u00e9n","year":"2012","unstructured":"Bod\u00e9n R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69(7):715\u201321.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"4008_CR61","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/ajo.12986","volume":"60","author":"M Galbally","year":"2020","unstructured":"Galbally M, Frayne J, Watson SJ, Morgan V, Snellen M. The association between gestational diabetes mellitus, antipsychotics and severe mental illness in pregnancy: A multicentre study. Aust N Z J Obstet Gynaecol. 2020;60(1):63\u20139.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"12","key":"4008_CR62","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1517\/14740338.2014.931368","volume":"13","author":"S Gentile","year":"2014","unstructured":"Gentile S. Pregnancy exposure to second-generation antipsychotics and the risk of gestational diabetes. Expert Opin Drug Saf. 2014;13(12):1583\u201390.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"4008_CR63","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1176\/appi.ajp.2018.17040393","volume":"175","author":"Y Park","year":"2018","unstructured":"Park Y, Hernandez-Diaz S, Bateman BT, Cohen JM, Desai RJ, Patorno E, et al. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. Am J Psychiatry. 2018;175(6):564\u201374.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"4008_CR64","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/schbul\/sbn107","volume":"36","author":"S Gentile","year":"2010","unstructured":"Gentile S. Antipsychotic therapy during early and late pregnancy. Systematic Rev Schizophrenia Bulletin. 2010;36(3):518\u201344.","journal-title":"Systematic Rev Schizophrenia Bulletin"},{"issue":"3","key":"4008_CR65","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/01.pra.0000351878.45260.94","volume":"15","author":"A Einarson","year":"2009","unstructured":"Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009;15(3):183\u201392.","journal-title":"J Psychiatr Pract"},{"issue":"5","key":"4008_CR66","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/JCP.0000000000000391","volume":"35","author":"N Terrana","year":"2015","unstructured":"Terrana N, Koren G, Pivovarov J, Etwel F, Nulman I. Pregnancy Outcomes Following In Utero Exposure to Second-Generation Antipsychotics: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol. 2015;35(5):559\u201365.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"4008_CR67","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1176\/appi.ajp.2015.15040506","volume":"173","author":"LS Cohen","year":"2016","unstructured":"Cohen LS, Viguera AC, Mcinerney KA, Freeman MP, Sosinsky AZ, Moustafa D, et al. Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Am J Psychiatry. 2016;173(3):263\u201370.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"4008_CR68","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40263-018-0517-5","volume":"32","author":"P Damkier","year":"2018","unstructured":"Damkier P, Videbech P. The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review. CNS Drugs. 2018;32(4):351\u201366.","journal-title":"CNS Drugs"},{"issue":"4","key":"4008_CR69","doi-asserted-by":"publisher","first-page":"20m13745","DOI":"10.4088\/JCP.20m13745","volume":"82","author":"AC Viguera","year":"2021","unstructured":"Viguera AC, Freeman MP, G\u00f3ez-Mogoll\u00f3n L, Sosinsky AZ, Mcelheny SA, Church TR, et al. Reproductive Safety of Second-Generation Antipsychotics: Updated Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. J Clin Psychiatry. 2021;82(4):20m13745.","journal-title":"J Clin Psychiatry."},{"issue":"11","key":"4008_CR70","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00228-021-03169-y","volume":"77","author":"M Ellfolk","year":"2021","unstructured":"Ellfolk M, Leinonen MK, Gissler M, Kiuru-Kuhlefelt S, Saastamoinen L, Malm H. Second-generation antipsychotic use during pregnancy and risk of congenital malformations. Eur J Clin Pharmacol. 2021;77(11):1737\u201345.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"4008_CR71","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1001\/jamapsychiatry.2016.1520","volume":"73","author":"KF Huybrechts","year":"2016","unstructured":"Huybrechts KF, Hernandez-Diaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, et al. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiat. 2016;73(9):938\u201346.","journal-title":"JAMA Psychiat"},{"issue":"3","key":"4008_CR72","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1017\/S1092852916000699","volume":"22","author":"S Gentile","year":"2017","unstructured":"Gentile S, Fusco ML. Neurodevelopmental outcomes in infants exposed in utero to antipsychotics: a systematic review of published data. CNS Spectr. 2017;22(3):273\u201381.","journal-title":"CNS Spectr"},{"key":"4008_CR73","doi-asserted-by":"crossref","unstructured":"Momen NC, Robakis T, Liu X, Reichenberg A, Bergink V, Munk-Olsen T. In utero exposure to antipsychotic medication and psychiatric outcomes in the offspring.\u00a0Neuropsychopharmacology. 2022;47(3):759\u201366.","DOI":"10.1038\/s41386-021-01223-y"},{"issue":"4","key":"4008_CR74","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00737-021-01115-6","volume":"24","author":"MP Freeman","year":"2021","unstructured":"Freeman MP, Viguera AC, G\u00f3ez-Mogoll\u00f3n L, Young AV, Caplin PS, Mcelheny SA, et al. Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Arch Womens Ment Health. 2021;24(4):659\u201367.","journal-title":"Arch Womens Ment Health"},{"issue":"4","key":"4008_CR75","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/pds.3749","volume":"24","author":"F Bellet","year":"2015","unstructured":"Bellet F, Beyens MN, Bernard N, Beghin D, Elefant E, Vial T. Exposure to aripiprazole during embryogenesis: a prospective multicenter cohort study. Pharmacoepidemiol Drug Saf. 2015;24(4):368\u201380.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"4008_CR76","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/JCP.0b013e318295fe12","volume":"33","author":"F Habermann","year":"2013","unstructured":"Habermann F, Fritzsche J, Fuhlbruck F, Wacker E, Allignol A, Weber-Schoendorfer C, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453\u201362.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"4008_CR77","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40360-019-0330-x","volume":"20","author":"I Ballester-Gracia","year":"2019","unstructured":"Ballester-Gracia I, Perez-Almarcha M, Galvez-Llompart A, Hernandez-Viadel M. Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report. BMC Pharmacol Toxicol. 2019;20(1):52.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"4008_CR78","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/JCP.0b013e318222bc65","volume":"31","author":"S Gentile","year":"2011","unstructured":"Gentile S, Tofani S, Bellantuono C. Aripiprazole and pregnancy: a case report and literature review. J Clin Psychopharmacol. 2011;31(4):531\u20132.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"4008_CR79","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/JCP.0b013e3181d27c7d","volume":"30","author":"UC Lutz","year":"2010","unstructured":"Lutz UC, Hiemke C, Wiatr G, Farger G, Arand J, Wildgruber D. Aripiprazole in pregnancy and lactation: a case report. J Clin Psychopharmacol. 2010;30(2):204\u20135.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"4008_CR80","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1345\/aph.1G507","volume":"40","author":"DN Mendhekar","year":"2006","unstructured":"Mendhekar DN, Sharma JB, Srilakshmi P. Use of aripiprazole during late pregnancy in a woman with psychotic illness. Ann Pharmacother. 2006;40(3):575.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"4008_CR81","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1399-5618.2006.00316.x","volume":"8","author":"DN Mendhekar","year":"2006","unstructured":"Mendhekar DN, Sunder KR, Andrade C. Aripiprazole use in a pregnant schizoaffective woman. Bipolar Disord. 2006;8(3):299\u2013300.","journal-title":"Bipolar Disord"},{"issue":"3","key":"4008_CR82","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00737-008-0022-9","volume":"11","author":"B Mervak","year":"2008","unstructured":"Mervak B, Collins J, Valenstein M. Case report of aripiprazole usage during pregnancy. Arch Womens Ment Health. 2008;11(3):249\u201350.","journal-title":"Arch Womens Ment Health"},{"issue":"3","key":"4008_CR83","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/JCP.0b013e318218c400","volume":"31","author":"N Watanabe","year":"2011","unstructured":"Watanabe N, Kasahara M, Sugibayashi R, Nakamura T, Nakajima K, Watanabe O, et al. Perinatal use of aripiprazole: a case report. J Clin Psychopharmacol. 2011;31(3):377\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"4008_CR84","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1055\/s-0032-1312591","volume":"45","author":"CG Widschwendter","year":"2012","unstructured":"Widschwendter CG, Hofer A. Aripiprazole use in early pregnancy: a case report. Pharmacopsychiatry. 2012;45(7):299\u2013300.","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"4008_CR85","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/JCP.0000000000000171","volume":"34","author":"E Windhager","year":"2014","unstructured":"Windhager E, Kim SW, Saria A, Zauner K, Amminger PG, Klier CM. Perinatal use of aripiprazole: plasma levels, placental transfer, and child outcome in 3 new cases. J Clin Psychopharmacol. 2014;34(5):637\u201341.","journal-title":"J Clin Psychopharmacol"},{"key":"4008_CR86","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jad.2018.06.004","volume":"238","author":"M Galbally","year":"2018","unstructured":"Galbally M, Frayne J, Watson SJ, Snellen M. Aripiprazole and pregnancy: A retrospective, multicentre study. J Affect Disord. 2018;238:593\u20136.","journal-title":"J Affect Disord"},{"issue":"11","key":"4008_CR87","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s40264-017-0560-z","volume":"40","author":"T Sakai","year":"2017","unstructured":"Sakai T, Ohtsu F, Mori C, Tanabe K, Goto N. Signal of Miscarriage with Aripiprazole: A Disproportionality Analysis of the Japanese Adverse Drug Event Report Database. Drug Saf. 2017;40(11):1141\u20136.","journal-title":"Drug Saf"},{"issue":"6","key":"4008_CR88","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3109\/00048674.2011.566547","volume":"45","author":"T Nguyen","year":"2011","unstructured":"Nguyen T, Teoh S, Hackett LP, Ilett K. Placental transfer of aripiprazole. Aust N Z J Psychiatry. 2011;45(6):500\u20131.","journal-title":"Aust N Z J Psychiatry"},{"issue":"3","key":"4008_CR89","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1017\/S1461145707007602","volume":"10","author":"P Schlotterbeck","year":"2007","unstructured":"Schlotterbeck P, Leube D, Kircher T, Hiemke C, Grunder G. Aripiprazole in human milk. Int J Neuropsychopharmacol. 2007;10(3):433.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"4008_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevNeurobiol.v14.i1.10","volume":"14","author":"BG Elvev\u00e5g","year":"2000","unstructured":"Elvev\u00e5g BG, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14(1):1\u201321.","journal-title":"Crit Rev Neurobiol"},{"issue":"10039","key":"4008_CR91","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","volume":"388","author":"MJ Owen","year":"2016","unstructured":"Owen MJ, Sawa A, Mortensen PB. Schizophrenia. The Lancet. 2016;388(10039):86\u201397.","journal-title":"The Lancet"},{"issue":"3","key":"4008_CR92","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1176\/appi.ajp.163.3.418","volume":"163","author":"CR Bowie","year":"2006","unstructured":"Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry. 2006;163(3):418\u201325.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"4008_CR93","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1176\/appi.ajp.162.3.495","volume":"162","author":"P Milev","year":"2005","unstructured":"Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162(3):495\u2013506.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"4008_CR94","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2165\/00003495-200666110-00004","volume":"66","author":"PD Harvey","year":"2006","unstructured":"Harvey PD, Mcclure MM. Pharmacological approaches to the management of cognitive dysfunction in schizophrenia. Drugs. 2006;66(11):1465\u201373.","journal-title":"Drugs"},{"issue":"3","key":"4008_CR95","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0165-1781(91)90065-W","volume":"37","author":"JA Sweeney","year":"1991","unstructured":"Sweeney JA, Keilp JG, Haas GL, Hill J, Weiden PJ. Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res. 1991;37(3):297\u2013308.","journal-title":"Psychiatry Res"},{"issue":"2","key":"4008_CR96","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","volume":"25","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY, Mcgurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25(2):233\u201355.","journal-title":"Schizophr Bull"},{"issue":"6","key":"4008_CR97","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","volume":"64","author":"RS Keefe","year":"2007","unstructured":"Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64(6):633\u201347.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"4008_CR98","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/acps.12374","volume":"131","author":"RE Nielsen","year":"2015","unstructured":"Nielsen RE, Levander S, Kjaersdam Telleus G, Jensen SO, Ostergaard Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia\u2013a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015;131(3):185\u201396.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"4008_CR99","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00228-013-1600-y","volume":"70","author":"G Desamericq","year":"2014","unstructured":"Desamericq G, Schurhoff F, Meary A, Szoke A, Macquin-Mavier I, Bachoud-Levi AC, et al. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol. 2014;70(2):127\u201334.","journal-title":"Eur J Clin Pharmacol"},{"key":"4008_CR100","doi-asserted-by":"crossref","unstructured":"Murphy A, Dursun S, Mckie S, Elliott R, Deakin JF. An investigation into aripiprazole\u2019s partial D(2) agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers. Psychopharmacol. 2016;233(8):1415\u201326.","DOI":"10.1007\/s00213-016-4234-9"},{"issue":"3","key":"4008_CR101","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00213-006-0428-x","volume":"187","author":"RS Kern","year":"2006","unstructured":"Kern RS, Green MF, Cornblatt BA, Owen JR, Mcquade RD, Carson WH, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacol. 2006;187(3):312\u201320.","journal-title":"Psychopharmacol"},{"issue":"4","key":"4008_CR102","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.euroneuro.2013.12.009","volume":"24","author":"A Maat","year":"2014","unstructured":"Maat A, Cahn W, Gijsman HJ, Hovens JE, Kahn RS, Aleman A. Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. Eur Neuropsychopharmacol. 2014;24(4):575\u201384.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"4008_CR103","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pnpbp.2010.10.021","volume":"35","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Gen K, Inoue Y. An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):161\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"4008_CR104","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/0269881111405555","volume":"26","author":"N Yasui-Furukori","year":"2012","unstructured":"Yasui-Furukori N, Kaneda A, Sugawara N, Tomita T, Kaneko S. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. J Psychopharmacol (Oxford, England). 2012;26(6):806\u201312.","journal-title":"J Psychopharmacol (Oxford, England)"},{"issue":"3","key":"4008_CR105","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/WNF.0b013e3181d52b85","volume":"33","author":"SW Kim","year":"2010","unstructured":"Kim SW, Shin IS, Kim JM, Bae KY, Yang SJ, Yoon JS. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin Neuropharmacol. 2010;33(3):121\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"4008_CR106","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1055\/s-0030-1254093","volume":"43","author":"N Pfaffenberger","year":"2010","unstructured":"Pfaffenberger N, Hoertnagl C, Fleischhacker WW, Hofer A. Aripiprazole add-on treatment in a patient with schizoaffective disorder: neurocognitive outcomes. Pharmacopsychiatry. 2010;43(6):234\u20135.","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"4008_CR107","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1055\/s-0029-1239539","volume":"43","author":"M Riedel","year":"2010","unstructured":"Riedel M, Spellmann I, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, et al. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry. 2010;43(2):50\u20137.","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"4008_CR108","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/pcn.12374","volume":"70","author":"H Suzuki","year":"2016","unstructured":"Suzuki H, Sekiguchi G. Influence of aripiprazole once monthly on clinical symptoms and cognitive function in two schizophrenia patients: Preliminary results. Psychiatry Clin Neurosci. 2016;70(1):71\u20132.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"3","key":"4008_CR109","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3109\/08039488.2013.799228","volume":"68","author":"CB Yeh","year":"2014","unstructured":"Yeh CB, Huang YS, Tang CS, Wang LJ, Chou WJ, Chou MC, et al. Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia. Nord J Psychiatry. 2014;68(3):219\u201324.","journal-title":"Nord J Psychiatry"},{"issue":"5","key":"4008_CR110","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1176\/appi.ajp.2010.10060855","volume":"168","author":"T Wykes","year":"2011","unstructured":"Wykes T, Huddy V, Cellard C, Mcgurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168(5):472\u201385.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"4008_CR111","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","volume":"76","author":"T Masuda","year":"2019","unstructured":"Masuda T, Misawa F, Takase M, Kane JM, Correll CU. Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies. JAMA Psychiat. 2019;76(10):1052\u201362.","journal-title":"JAMA Psychiat"},{"issue":"3","key":"4008_CR112","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jamapsychiatry.2013.3726","volume":"71","author":"SM Hartz","year":"2014","unstructured":"Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, Knowles JA, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiat. 2014;71(3):248\u201354.","journal-title":"JAMA Psychiat"},{"issue":"1\u20133","key":"4008_CR113","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.schres.2007.11.034","volume":"100","author":"MS Swartz","year":"2008","unstructured":"Swartz MS, Wagner HR, Swanson JW, Stroup TS, Mcevoy JP, Reimherr F, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res. 2008;100(1\u20133):39\u201352.","journal-title":"Schizophr Res"},{"issue":"3","key":"4008_CR114","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1081\/ADA-100100248","volume":"26","author":"CD Swofford","year":"2000","unstructured":"Swofford CD, Scheller-Gilkey G, Miller AH, Woolwine B, Mance R. Double jeopardy: schizophrenia and substance use. Am J Drug Alcohol Abuse. 2000;26(3):343\u201353.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"3","key":"4008_CR115","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/01.nmd.0000202575.79453.6e","volume":"194","author":"MS Swartz","year":"2006","unstructured":"Swartz MS, Wagner HR, Swanson JW, Stroup TS, Mcevoy JP, Canive JM, et al. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis. 2006;194(3):164\u201372.","journal-title":"J Nerv Ment Dis"},{"issue":"6","key":"4008_CR116","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/jnnp.2005.079228","volume":"77","author":"S Potvin","year":"2006","unstructured":"Potvin S, Pampoulova T, Mancini-Mari\u00eb A, Lipp O, Bouchard RH, Stip E. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry. 2006;77(6):796\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"4008_CR117","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/00952990701764631","volume":"34","author":"S Potvin","year":"2008","unstructured":"Potvin S, Stip E, Lipp O, Roy MA, Demers MF, Bouchard RH, et al. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia. Am J Drug Alcohol Abuse. 2008;34(1):75\u201382.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"4008_CR118","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/acps.13291","volume":"144","author":"M L\u00e4hteenvuo","year":"2021","unstructured":"L\u00e4hteenvuo M, Batalla A, Luykx JJ, Mittendorfer-Rutz E, Tanskanen A, Tiihonen J, et al. Morbidity and mortality in schizophrenia with comorbid substance use disorders. Acta Psychiatr Scand. 2021;144(1):42\u20139.","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"4008_CR119","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1521-0391.2011.00150.x","volume":"20","author":"ZS Meszaros","year":"2011","unstructured":"Meszaros ZS, Dimmock JA, Ploutz-Snyder RJ, Abdul-Malak Y, Leontieva L, Canfield K, et al. Predictors of smoking severity in patients with schizophrenia and alcohol use disorders. Am J Addict. 2011;20(5):462\u20137.","journal-title":"Am J Addict"},{"issue":"11","key":"4008_CR120","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1176\/appi.ajp.157.11.1835","volume":"157","author":"TP George","year":"2000","unstructured":"George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157(11):1835\u201342.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"4008_CR121","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/14656566.2016.1114101","volume":"17","author":"J-M Azorin","year":"2016","unstructured":"Azorin J-M, Simon N, Adida M, Belzeaux R. Pharmacological treatment of schizophrenia with comorbid substance use disorder. Expert Opin Pharmacother. 2016;17(2):231\u201353.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"4008_CR122","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jsat.2007.01.008","volume":"34","author":"Al Green","year":"2008","unstructured":"Green Al, Noordsy DL, Brunette MF, O\u2019keefe C. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Substance Abuse Treatment. 2008;34(1):61\u201371.","journal-title":"J Substance Abuse Treatment"},{"issue":"2","key":"4008_CR123","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/hup.1089","volume":"25","author":"SH Kim","year":"2010","unstructured":"Kim SH, Han DH, Joo SY, Min KJ. The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia. Hum Psychopharmacol. 2010;25(2):187\u201390.","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"4008_CR124","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/01.jcp.0000169419.38899.5b","volume":"25","author":"TP Beresford","year":"2005","unstructured":"Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol. 2005;25(4):363\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"4008_CR125","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2147\/NDT.S171002","volume":"14","author":"I Cuomo","year":"2018","unstructured":"Cuomo I, Kotzalidis GD, De Persis S, Piacentino D, Perrini F, Amici E, et al. Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life. Neuropsychiatr Dis Treat. 2018;14:1645\u201356.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"4008_CR126","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/JCP.0000000000001087","volume":"39","author":"SF Chen","year":"2019","unstructured":"Chen SF, Shen YC. Long-Acting Injectable Aripiprazole for a Schizophrenic Patient Concomitant With Stimulant Use Disorder. J Clin Psychopharmacol. 2019;39(5):508\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"4008_CR127","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/JCP.0b013e31828b2575","volume":"33","author":"BJ Wu","year":"2013","unstructured":"Wu BJ, Chen HK, Lee SM. Do atypical antipsychotics really enhance smoking reduction more than typical ones?: the effects of antipsychotics on smoking reduction in patients with schizophrenia. J Clin Psychopharmacol. 2013;33(3):319\u201328.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"4008_CR128","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40801-020-00178-8","volume":"7","author":"N Szerman","year":"2020","unstructured":"Szerman N, Basurte-Villamor I, Vega P, Martinez-Raga J, Parro-Torres C, Cambra Almerge J, et al. Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study. Drugs - real world outcomes. 2020;7(1):75\u201383.","journal-title":"Drugs - real world outcomes"},{"issue":"11","key":"4008_CR129","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/0706743717718167","volume":"62","author":"D Siskind","year":"2017","unstructured":"Siskind D, Siskind V, Kisely S. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Canadian J Psychiatry Revue Canadienne De Psychiatrie. 2017;62(11):772\u20137.","journal-title":"Canadian J Psychiatry Revue Canadienne De Psychiatrie"},{"issue":"3","key":"4008_CR130","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1590\/S1516-44462007000300007","volume":"29","author":"J Henna Neto","year":"2007","unstructured":"Henna Neto J, Elkis H. Clinical aspects of super-refractory schizophrenia: a 6-month cohort observational study. Revista brasileira de psiquiatria. 2007;29(3):228\u201332.","journal-title":"Revista brasileira de psiquiatria"},{"issue":"8","key":"4008_CR131","doi-asserted-by":"publisher","first-page":"429","DOI":"10.5498\/wjp.v11.i8.429","volume":"11","author":"S Chakrabarti","year":"2021","unstructured":"Chakrabarti S. Clozapine resistant schizophrenia: Newer avenues of management. World J Psychiatry. 2021;11(8):429\u201348.","journal-title":"World J Psychiatry"},{"issue":"1","key":"4008_CR132","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/00002826-200601000-00009","volume":"29","author":"F Mouaffak","year":"2006","unstructured":"Mouaffak F, Tranulis C, Gourevitch R, Poirier MF, Douki S, Oli\u00e9 JP, et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol. 2006;29(1):28\u201333.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"4008_CR133","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.euroneuro.2011.08.005","volume":"22","author":"S Porcelli","year":"2012","unstructured":"Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol. 2012;22(3):165\u201382.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"4008_CR134","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1177\/0004867418772351","volume":"52","author":"DJ Siskind","year":"2018","unstructured":"Siskind DJ, Lee M, Ravindran A, Zhang Q, Ma E, Motamarri B, et al. Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Aust N Z J Psychiatry. 2018;52(8):751\u201367.","journal-title":"Aust N Z J Psychiatry"},{"issue":"3","key":"4008_CR135","first-page":"Cd006324","volume":"3","author":"S Barber","year":"2017","unstructured":"Barber S, Olotu U, Corsi M, Cipriani A. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2017;3(3):Cd006324.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4008_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02849987","volume":"24","author":"Y Gen\u00e7","year":"2007","unstructured":"Gen\u00e7 Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther. 2007;24(1):1\u201313.","journal-title":"Adv Ther"},{"issue":"4","key":"4008_CR137","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JCP.0b013e318296884f","volume":"33","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Accordini S, Nos\u00e8 M, Purgato M, Girlanda F, Tansella M, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. J Clin Psychopharmacol. 2013;33(4):533\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"4008_CR138","doi-asserted-by":"publisher","first-page":"720","DOI":"10.4088\/JCP.v69n0505","volume":"69","author":"JS Chang","year":"2008","unstructured":"Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5):720\u201331.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"4008_CR139","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/acps.13228","volume":"142","author":"E Wagner","year":"2020","unstructured":"Wagner E, Mcmahon L, Falkai P, Hasan A, Siskind D. Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis. Acta Psychiatr Scand. 2020;142(6):456\u201366.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"4008_CR140","doi-asserted-by":"publisher","first-page":"e20476","DOI":"10.1371\/journal.pone.0020476","volume":"6","author":"R Boulkedid","year":"2011","unstructured":"Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS ONE. 2011;6(6):e20476.","journal-title":"PLoS ONE"},{"issue":"4","key":"4008_CR141","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.dld.2019.10.015","volume":"52","author":"X H\u00e9buterne","year":"2020","unstructured":"H\u00e9buterne X, Peyrin-Biroulet L, Hausfater P. The management of emergency hospital visits for inflammatory bowel diseases: A French national expert consensus report. Dig Liver Dis. 2020;52(4):420\u20136.","journal-title":"Dig Liver Dis"},{"issue":"9","key":"4008_CR142","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1111\/add.15411","volume":"116","author":"J Castro-Calvo","year":"2021","unstructured":"Castro-Calvo J, King DL, Stein DJ, Brand M, Carmi L, Chamberlain SR, et al. Expert appraisal of criteria for assessing gaming disorder: an international Delphi study. Addiction (Abingdon, England). 2021;116(9):2463\u201375.","journal-title":"Addiction (Abingdon, England)"},{"issue":"4","key":"4008_CR143","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/da.23135","volume":"38","author":"YE Rybak","year":"2021","unstructured":"Rybak YE, Lai KSP, Ramasubbu R, Vila-Rodriguez F, Blumberger DM, Chan P, et al. Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment. Depress Anxiety. 2021;38(4):456\u201367.","journal-title":"Depress Anxiety"},{"issue":"5 Suppl 1","key":"4008_CR144","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/01.jcp.0000142281.85207.d5","volume":"24","author":"JW Newcomer","year":"2004","unstructured":"Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol. 2004;24(5 Suppl 1):S1-6.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"4008_CR145","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1185\/030079906X167444","volume":"23","author":"RH Perlis","year":"2007","unstructured":"Perlis RH. Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians. Curr Med Res Opin. 2007;23(3):467\u201375.","journal-title":"Curr Med Res Opin"},{"key":"4008_CR146","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jad.2020.09.098","volume":"279","author":"SS Wahid","year":"2021","unstructured":"Wahid SS, Ottman K, Hudhud R, Gautam K, Fisher HL, Kieling C, et al. Identifying risk factors and detection strategies for adolescent depression in diverse global settings: A Delphi consensus study. J Affect Disord. 2021;279:66\u201374.","journal-title":"J Affect Disord"},{"issue":"3","key":"4008_CR147","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.2196\/jmir.6.3.e30","volume":"6","author":"P Leece","year":"2004","unstructured":"Leece P, Bhandari M, Sprague S, Swiontkowski MF, Schemitsch EH, Tornetta P, et al. Internet versus mailed questionnaires: a randomized comparison (2). J Med Internet Res. 2004;6(3):e30.","journal-title":"J Med Internet Res"},{"key":"4008_CR148","doi-asserted-by":"crossref","unstructured":"Pit SW, Vo T, Pyakurel S. The effectiveness of recruitment strategies on general practitioner\u2019s survey response rates - a systematic review. BMC Med Res Methodol. 2014;14:76.","DOI":"10.1186\/1471-2288-14-76"},{"issue":"4","key":"4008_CR149","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/0163278707307899","volume":"30","author":"JB Vangeest","year":"2007","unstructured":"Vangeest JB, Johnson TP, Welch VL. Methodologies for improving response rates in surveys of physicians: a systematic review. Eval Health Prof. 2007;30(4):303\u201321.","journal-title":"Eval Health Prof"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04008-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-04008-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04008-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T09:41:42Z","timestamp":1700646102000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-04008-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":149,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4008"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-04008-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]},"assertion":[{"value":"24 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The tagging of the author\u2019s name was incorrect in the original publication. The article has been updated to rectify the error.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since no individual patient data was collected in the course of this study, and physician participation was voluntary, ethical committee approval was not necessary. The survey was conducted in the accordance with the code for data privacy of the French data protection agency (<i>Commission Nationale de l'Informatique et des Libert\u00e9s<\/i>). The online survey interface provided information on the goals and procedures of the study and required participants to provide explicit consent to participate in the survey, on the basis of the information provided, before proceeding to the study questionnaire.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MR is an employee of Lundbeck France, who market treatments for schizophrenia, including an injectable depot formulation of aripiprazole. PML received financial support from Otsuka and Lundbeck for the organization of meetings of the scientific committee, for the implementation of the survey and for editorial support, personal fee from Janssen, Eisai, Neuraxpharm, and Ethypharm, support for meeting from Eisai, Lundbeck and Ethypharm, and fee for advisory boards from Janssen, Eisai and Lundbeck. PN received honoraria from Otsuka and Lundbeck. EF received consulting fees from Bristol Myers Squibb, Janssen-Cilag, Lilly, Lundbeck, Otsuka, Recordatti, Sanofi and honoraria as speaker from Abbvie, AstraZeneca, Bristol Myers Squibb, Janssen-Cilag, Lundbeck, Otsuka, MSD, and Sanofi. IA was occasionally expert on reports and for consulting activities for Otsuka, Janssen, BMS, Astrazeneca and Lundbeck and was invited as speaker and auditor for conferences by Otsuka, Janssen, BMS and Astrazeneca. DD received honoraria as speaker from Janssen Cilag and Eisai, and for advisory boards from Lundbeck, Ethyfarm, Janssen and Eisai. WEH received grants from le Conseil R\u00e9gional du Centre-Val de Loire, la Fondation de France and le Minist\u00e8re de la Sant\u00e9, consulting fees from Air Liquide, Janssen, Lundbeck and Otsuka, honoraria from Eisai, Chugai and UCB, payments from Mapreg SAS, and supports for attending meetings and participating on advisory boards from Janssen and Lundbeck. RJ received support from Lundbeck and Otsuka for the manuscript, grants from FIOP national grant and Institut Universitaire de France, supports for attending meeting from Lundbeck and for participating on advisory boards from Otsuka and Lundbeck. SM received honoraria as consultant and lecturer from Lundbeck, Otsuka, Janssen, Eisai, GSK and Pfizer. MR is an employee of Lundbeck France, who market treatments for schizophrenia, including an injectable depot formulation of aripiprazole. NS received support from Lundbeck and Otsuka for the manuscript, consulting fees from Tempero Bio and Aelis Farma, support for attending meetings from Camarus, and for participation on advisory boards from Bioproject. MNV has no conflict of interest to declare. JMA received honoraria or research or educational conference grants from Lundbeck and Otsuka.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"364"}}